Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Puma Biotechnology announced the launch of Nerlynx (neratinib) for the extended adjuvant treatment of adults with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy.
The approval was supported by data from the Phase 3 multicenter, randomized, double-blind, placebo-controlled ExteNET trial (n=2,840) following adjuvant treatment with trastuzumab. Women with early stage HER2+ breast cancer were randomized to either Nerlynx or placebo for 1 year. The data showed invasive disease-free survival (iDFS) was seen in 94.2% of patients treated with Nerlynx vs. 91.9% in patients who received placebo after follow-up of 2 years (hazard ratio [HR] 0.66, 95% CI: 0.49, 0.90; P=0.008).
The most frequently reported adverse effects were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST/ALT increase, nail disorder, dry skin, abdominal distention, epistaxis, weight loss, and urinary tract infection.
Nerlynx, a kinase inhibitor, initially received approval from the Food and Drug Administration (FDA) in July 2017. Nerlynx is available as 40mg strength tablets in 126- and 180-count bottles.
For more information call (844) 637-5969 or visit Nerlynx.com.
